Evidence map›Paper›PMID 15502928›Full record

ReviewDiabetologia2004

From beast to bedside: a commentary.

A A Rossini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The role of innate immune pathways in type 1 diabetes pathogenesis.Current opinion in endocrinology, diabetes, and obesity · 2010
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

A A RossiniDiabetes Division, Department of Medicine, The University of Massachusetts Medical School, 373 Plantation Street, Biotech 2, Suite 218, Worcester, MA 01605, USA. aldo.rossini@umassmed.edu

Funding

Virology and Technology CoreP01AI046629 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREINER, DALE LESLIE · 1999 to 2014
$19.1M
PILOT AND FEASIBILITY PROGRAMP30DK032520 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1986 to 2010
$14.6M
ROLE OF CBL AND PHOSPHATIDYLINOSITOL 3-KINASE IN CD40 SIGNALINGP01DK053006 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROCK, KENNETH L · 1997 to 2007
$8.9M
ISLET TOLERANCE INDUCTION BASED ON ANTI-CD154 ANTIBODYR01DK056946 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROSSINI, ALDO A · 2000 to 2006
$3.8M
EXPERIMENTAL JUVENILE TYPE DIABETESR01DK025306 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREINER, DALE LESLIE · 1994 to 2008
$3.8M
EXPERIMENTAL JUVENILE-TYPE DIABETESR37DK025306 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROSSINI, ALDO A · 1986 to 1993
–
NIAID NIH HHS AI46629NIDDK NIH HHS DK25306NIDDK NIH HHS DK32520NIDDK NIH HHS DK53006NIDDK NIH HHS DK56946
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease Models, AnimalHumansRats

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.